AI Wound Alert & Home Management for Recurrent DFU
Building an Artificial Intelligence-Driven Early Warning System and Home Management Protocol for a Diabetic Foot Ulcer Recurrence Cohort
Diabetes is one of the major chronic diseases, and diabetic foot ulcer (DFU) is a significant adverse prognosis of diabetes. The recurrence of DFU after healing involves multiple risk factors, such as changes in foot loading patterns, patient compliance, family care capacity, blood glucose monitoring, the degree of ischemia, and control of systemic diseases. Early identification of signs of DFU recurrence and timely follow-up interventions are crucial for improving prognosis, reducing disability rates, and lowering healthcare costs. However, traditional follow-up systems lack individualized strategies (e.g., insufficient risk stratification, rigid follow-up intervals, inadequate compliance management), often resulting in low follow-up efficacy. High-risk patients prone to recurrence may not receive frequent enough follow-ups for early detection, while low-risk patients unlikely to recur may undergo multiple unnecessary visits, increasing the burden on both patients and healthcare providers. This inefficiency is a key reason for the persistently high rates of disability and mortality among patients with recurrent DFU. Establishing individualized follow-up strategies for DFU, leveraging advanced technologies to address core bottlenecks such as delayed recurrence warnings and insufficient home management, represents an effective technical approach to solving these problems.
Our center aims to establish and refine a specialized cohort for active DFU follow-up, along with a multimodal database with comprehensive indicators. We plan to explore a high-risk foot grading system for preventing DFU recurrence and develop targeted follow-up protocols. Using AI technology, we will create a wound alert system capable of identifying DFU recurrence and explore a remote healthcare and AI-assisted prevention and control system for DFU recurrence, centered on patient self-management at home.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Long Executive Deputy Director, Medical Doctor
- Phone Number: +86 010-82266699
- Email: liyunfeng1106@163.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100191
- Peking University Third Hospital
-
Contact:
- Yunfeng Li, Medical Doctor
- Phone Number: +86 010-82267791
- Email: liyunfeng1106@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- A diagnosis of type 1 or type 2 diabetes in accordance with the definitions set by the World Health Organization;
- The wound was caused by diabetic foot*. After treatment, the wound healed. The criteria for successful healing were as follows: the wound was dry with no exudate; the wound bed and edges were completely epithelialized; there were no signs of redness or swelling in the surrounding area; and the wound had sufficient tensile strength to withstand pressure without cracking;
- Voluntarily participated in this study and signed the informed consent form.
Exclusion Criteria:
- The patient is unable to cooperate or has a mental disorder;
- At the discretion of the researchers, the subject is not suitable for this study or is unable to comply with the requirements of this study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
The population with DFU recovery
The wound was caused by diabetic foot.
After treatment, the wound healed.
The healing criteria were as follows: the wound was dry with no exudate; the wound bed and edges were completely epithelialized; there were no signs of redness or swelling in the surrounding area; and the wound had sufficient tensile strength to withstand pressure without cracking
|
Re-classification system for high-risk feet, along with individualized follow-up care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1-year recurrence rate of diabetic foot
Time Frame: 1-year
|
Recurrence rate of diabetic foot = (Number of diabetic foot patients who experience ulcer recurrence within 1 year) / (Total number of diabetic foot patients whose ulcers have healed) × 100%
|
1-year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients with Wagner grade 1/2 among those who experienced DFU recurrence within 1 year of follow-up
Time Frame: 1-year
|
Number of patients with Wagner stage 1/2 among those who experienced DFU recurrence within 1 year of follow-up / Total number of patients who experienced DFU recurrence within 1 year of follow-up
|
1-year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Disease Attributes
- Diabetes Mellitus
- Diabetic Angiopathies
- Diabetes Complications
- Skin Diseases
- Skin Ulcer
- Leg Ulcer
- Diabetic Neuropathies
- Foot Ulcer
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Recurrence
- Diabetic Foot
Other Study ID Numbers
Other Study ID Numbers
- Long2025-DFU-recurrence cohort
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer (DFU)
-
NCT07222540Temporarily not availableNeuropathic Diabetic Ulcer - Foot | Diabetic Foot Disease | DFU
-
NCT07206862Not yet recruitingDiabetic Foot Wounds | Diabetic Foot Ulcer (DFU) | Diabetic Foot Ulcer Treatment
-
NCT07449975Not yet recruitingDiabetic Foot | Foot Ulcer | Ulcer Foot | Diabetic Foot Ulcer (DFU)
-
NCT07414368Enrolling by invitationUlcer | Chronic Ulcers | Diabetic Foot Ulcers (DFU) | DFU
-
NCT07466576Not yet recruiting
-
NCT07488247Recruiting
-
NCT07209475RecruitingDiabetic Foot Ulcer (DFU) | Amnio-Maxx
-
NCT07373327Not yet recruitingDiabetic Foot Ulcer (DFU)
-
NCT07360418RecruitingUlcer | Diabetic Foot Ulcer | Diabetic Foot Ulcers (DFU) | Foot Ulcer Chronic
Clinical Trials on Individualized follow-up care
-
NCT02935920Completed
-
NCT04703725CompletedInfertility | Psychological Distress | Infertility, Female | Depression, Anxiety | Nurse's Role
-
NCT03878043CompletedTraumatic Subdural Hematoma
-
NCT03502109CompletedCardiovascular Diseases | Hypertension | Type 2 Diabetes Mellitus | Dyslipidemias | Medication Adherence | Drug Use
-
NCT01710774Active, not recruitingDiabetic Foot | Foot Ulcer
-
NCT05264987CompletedCOVID-19 | Intensive Care Unit | Morality | Obstetric Anesthesia Problems